Windlas Biotech LTD IPO is all set to make a debut in the stock market with an issue size of 1838 Cr. Windlas Biotech Ltd is one of the leading companies in the pharmaceutical formulations contract development and manufacturing organizations (CDMO) segment in India.
Windlas Biotech LTD IPO -Overview
| Windlas Biotech Limited IPO Issue Date | 4- 6 August 2021 |
| Windlas Biotech Limited IPO Opening Date | 4 August 2021 |
| Windlas Biotech Limited IPO Face Value | INR 5 per share |
| Windlas Biotech Limited IPO Price | INR 401.54 per share |
| Windlas Biotech Limited IPO Lot Size | 30 Shares |
| Issue Size | 401.54 Cr |
| Offer for sale | 236.54 Cr |
| Issue Type | Book built Issue IPO |
| Listing At | BSE, NSE |
| QIB Shares Offered | 24.40 times |
| NII (HNI) Shares | 15.73 times |
| Company Promoters | Ashok Kumar Windlass, Hitesh Windlass, Manoj Kumar Windlass, and AKW WBL Family Pvt Trust are the company promoters. |
Windlas Biotech LTD IPO-Tentative Dates
| Windlas Biotech Limited IPO opening date | 4 August 2021 |
| Windlas Biotech Limited IPO closing date | 6 August 2021 |
| Basis of Allotment | 11 August 2021 |
| Initiation of Refunds | 12 August 2021 |
| The credit of Shares to Demat | 13 August 2021 |
| Windlas Biotech Limited IPO Listing Date | 17 August 2021 |
Windlas Biotech – Industry Overview.
The global pharmaceutical industry is characterized by the concentration of consumption, production, and innovation in a relatively small number of high-income countries which continue to account for a major portion of this market in value terms on account of higher-priced drugs and newer products. However, over the recent few years, production, as well as consumption, has started to shift to middle-income countries, such as India and China; these “Pha merging” markets also account for a higher share in volume terms and have outpaced growth in high-income markets. These double-digit-growth countries are now the strategic focus points for many multinational pharmaceutical companies. Though, for pharmaceutical research and development (“R&D”), high-income countries continue to dominate expenditure in both the public and private sectors.
Windlas Biotech Limited IPO – Company Overview
Windlas Biotech Ltd amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances, and low-solubility, they provide a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (“GMP”) with a focus on improved safety, efficacy and cost. fiscal 2020, the market share was 1.5% in terms of revenue in the domestic formulations CDMO industry. In addition to providing services and products in the CDMO market, they also sell their own branded products in the trade generics and OTC markets as well as export generic products to several countries.
Windlas Biotech Limited IPO-Objectives
- To purchase equipment required for capacity expansion of their existing facility at Dehradun Plant IV.
- To finance incremental working capital requirements of the company.
- Repayment/prepayment of company’s borrowings.
- General corporate purposes.
Windlas Biotech Limited IPO – Financial Statements
| Particulars | 31-Mar-21 | 31-Mar-20 | 31-Mar-19 |
| Total Assets | 2,961.23 | 3,384.88 | 2,981.80 |
| Total Revenue | 4,306.95 | 3,313.39 | 3,115.25 |
| Profit After Tax | 155.70 | 162.13 | 638.22 |
Windlas Biotech Limited IPO- Strengths
- Leading market player in the domestic pharmaceutical formulation CDMO segment.
- Strong focus on the chronic therapeutic category.
- state-of-the-art manufacturing facilities in Dehradun, Uttarakhand.
- Professional and experienced Promoters and a senior management team.
- An innovative product portfolio of complex generic products.
- Robust financial performance track record.
Windlas Biotech Limited IPO -Weakness
- Dependency on the success of its relationships with its CDMO customers, including leading Indian pharmaceutical companies and multinational companies.
- Highly competitive market.
Company Contact Information
Windlas Biotech Limited
40/1, Mohabewala Industrial Area,
Dehradun, 248110
Phone: +91 135 6608000
Email: grievance@windlasbiotech.com
Website: http://www.windlasbiotech.com/
Windlas Biotech IPO Registrar
Phone: +91-22-4918 6270
Email: windlas.ipo@linkintime.co.in
Website: https://linkintime.co.in/
Windlas Biotech IPO Lead Manager(s)
- DAM Capital Advisors Ltd (Formerly IDFC Securities Ltd) (Past IPO Performance)
- IIFL Securities Ltd (Past IPO Performance)
- SBI Capital Markets Limited (Past IPO Performance)
